

## Tentative Outline (Proposal)

### Special/Thematic Issue for the Journal "Current Alzheimer Research" (CAR)

#### Title of the Thematic Issue: Alzheimer's Disease Drug Development

*Name of Guest Editor: Dr. Leonidas D. Panos*

#### • **Scope of the Thematic Issue:**

Alzheimer's disease is a progressive neurodegenerative disorder that affects millions of people worldwide. Despite decades of research, no cure or disease-modifying treatment is available yet. Therefore, the need for developing effective therapies to treat Alzheimer's disease is an urgent matter. This special issue aims to provide a comprehensive overview of the current state of Alzheimer's disease drug development, identify the challenges, and propose future directions for drug discovery and development. We hope that this collection of articles will contribute to the development of effective therapies to treat Alzheimer's disease, improving the lives of millions of people affected by this devastating disorder.

**Keywords:** Alzheimer's Disease, antibody therapy, molecular targets, regenerative medicine, biomarker development, ethical considerations.

#### Sub-Topics:

- Overview of Alzheimer's disease pathogenesis and current treatment options.
- Molecular targets for Alzheimer's disease drug development.
- Challenges and opportunities in preclinical and clinical drug development for Alzheimer's disease.
- Innovative approaches for Alzheimer's disease drug development, including gene therapy and regenerative medicine.
- The role of artificial intelligence and machine learning in Alzheimer's disease drug discovery.
- The impact of precision medicine on Alzheimer's disease drug development.
- Biomarker development for Alzheimer's disease diagnosis and treatment monitoring.
- Clinical trial design and regulatory considerations in Alzheimer's disease drug development.
- Ethical considerations in Alzheimer's disease drug development, including the use of animal models and informed consent.
- Patient perspectives on Alzheimer's disease drug development and clinical trials.

#### Schedule:

- ✧ Complete Thematic Issue Submission Deadline: **December 31, 2023**

#### Contacts:

**Guest Editor Name:** Dr. Leonidas D. Panos

**Affiliation:** Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Switzerland

**Email:** [leonidas.panos@insel.ch](mailto:leonidas.panos@insel.ch); [ldpanos@yahoo.gr](mailto:ldpanos@yahoo.gr)